阿扎丙宗治疗类风湿性关节炎的潜力评估。

An assessment of the therapeutic potential of azapropazone in rheumatoid arthritis.

作者信息

Brooks P M, Mason D I, McNeil R, Anderson J A, Buchanan W W

出版信息

Curr Med Res Opin. 1976;4(1):50-6. doi: 10.1185/03007997609109281.

Abstract

A trial to compare the therapeutic potential of 1200 mg. azapropazone daily with 3.9 g. aspirin daily was carried out in 108 out-patients with rheumatoid arthritis over a 14-day period. Analysis of results from the 85 patients with completed assessment data (49 on azapropazone; 36 on aspirin) showed that azapropazone was better than aspirin from the point of view of pain relief, number of days patients were withdrawn prematurely from the trial, and patient satisfaction with treatment. The differences, however, were not statistically significant. The authors compare the results obtained in this trial with those obtained previously from trials with 13 other antirheumatic drugs using the same method.

摘要

一项针对108名类风湿性关节炎门诊患者进行了为期14天的试验，比较每日服用1200毫克阿扎丙宗与每日服用3.9克阿司匹林的治疗潜力。对85名有完整评估数据的患者（49名服用阿扎丙宗；36名服用阿司匹林）的结果分析表明，从缓解疼痛、患者提前退出试验的天数以及患者对治疗的满意度来看，阿扎丙宗优于阿司匹林。然而，这些差异无统计学意义。作者将该试验获得的结果与之前使用相同方法对其他13种抗风湿药物进行试验所获得的结果进行了比较。